Ronald Walsh
Cardiovascular Disease · Largo, FLNPI 1316909377
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,950 of the $15,998 with a category attached, or 68.4%. Pfizer accounts for 72.5% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $12,632 and has fallen 99.5% since, to $63 in 2025.
Across 184 payments — averaging $86.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$12K
- Boston Scientific$2K
- E.r. Squibb & Sons, L.L.C.$539
- Johnson & Johnson$381
- Abbott$273
- Merck$262
- plus $1K from 20 others
Across 15 payments — averaging $664.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$6K
- Esperion Therapeutics, Inc.$4K
What the payments were for
- Consulting fees$5003%
- Speaking & faculty fees$10,95068%
- Travel & lodging$640%
- Food & beverage$4,37427%
- Education$350%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 37 | $11,593 |
| Boston Scientific | 29 | $1,693 |
| E.r. Squibb & Sons, L.L.C. | 4 | $539 |
| Johnson & Johnson | 22 | $381 |
| Abbott | 11 | $273 |
| Merck | 15 | $262 |
| Sanofi-aventis U.S. LLC | 14 | $255 |
| Novartis | 12 | $186 |
| Medtronic(2 entities) | 6 | $152 |
| Amgen | 7 | $112 |
| Boehringer Ingelheim | 6 | $111 |
| Chiesi USA, Inc. | 1 | $75 |
| Bolton Medical Inc | 1 | $60 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $55 |
| Novo Nordisk | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Astellas Pharma US Inc | 1 | $23 |
| United Therapeutics Corporation | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Bayer | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,998 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $130,944 |
| EntrestoSacubitril/Valsartan | 24 | $39,646 |
| XareltoRivaroxaban | 38 | $28,233 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 19 | $5,799 |
| Nebivolol Hcl | 32 | $1,975 |
| Ezetimibe | 104 | $1,874 |
| Irbesartan | 74 | $1,366 |
| Metoprolol Succinate | 56 | $972 |
| Flecainide Acetate | 23 | $920 |
| Atorvastatin Calcium | 70 | $881 |
| Losartan Potassium | 89 | $750 |
| Rosuvastatin Calcium | 57 | $646 |
| SotalolSotalol Hcl | 16 | $644 |
| Bisoprolol Fumarate | 30 | $623 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 28 | $315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11,593 | $130,94496 claims |
| NovartisEntresto | $186 | $39,64624 claims |
| Johnson & JohnsonXarelto | $381 | $28,23338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Largo
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.